Icon

Actemra - (80mg/4mL, 200mg/10mL, 400mg/20mL; Injection, Intravenous)

tocilizumab Genentech, Inc.
80mg/4mL, 200mg/10mL, 400mg/20mL; Injection, Intravenous
More Than $1000 mn
None
Less Than 5
None None
None None
ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor indicated for treatment of Rheumatoid Arthritis : Adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Yes
*** ****** ** ** *********** ********. ** *** ****, ****** ************ ******* *** **** (*******) ** ***. ********* **** ****** ** *** **** **** ** ******* *** ** **. ********* ** *****'* ****** ****** ****, *** ***** ******* ****** *** ******* ******* *** **** ****** ******* *********** ** **** ****. ***** **** **** **** ****** ******.
Actemra Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20 Patent 21 Patent 22 Patent 23 Patent 24 Patent 25 Patent 26 Patent 27 Patent 28 Patent 29 Patent 30 Patent 31 Patent 32 Patent 33 Patent 34
****** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** *** ********* *** ********* *** ********* **** ** *** **, **** *** ********* *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** *** ********* **** ** *** **, **** *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** ******* **** ******* *** **** *** *** ****
  1. *** **, **** : ********* **** ****** **** ************ ** ******* '***, '***, '***, '****, '***, '***, '***, '***, '****, '****, '***, '***, '***, '***, '****, '***, '***, '***, '***, *** '***

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.